Depressed mood and suicidality in individuals exposed to tetrabenazine in a large huntington disease observational study

Journal of Huntington's Disease

Volumn 2, Issue 4, 2013, Pages 509-515

  Dorsey, E Ray ^a   Brocht, Alicia F D ^a   Nichols, Paige E ^b   Darwin, Kristin C ^b   Anderson, Karen E ^c   Beck, Christopher A ^a   Singh, Sonal ^b   Biglan, Kevin M ^a   Shoulson, Ira ^c  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Depression; Huntington disease; Suicide; Tetrabenazine; U.S. food and drug administration

Indexed keywords

ADRENERGIC RECEPTOR AFFECTING AGENT; TETRABENAZINE;

ADULT; ARTICLE; CHEMICALLY INDUCED DISORDER; DEPRESSION; FEMALE; HUMAN; HUNTINGTON CHOREA; MALE; MIDDLE AGED; PSYCHOLOGICAL ASPECT; SUICIDAL IDEATION; SUICIDE; U.S. FOOD AND DRUG ADMINISTRATION;

DEPRESSION; HUNTINGTON DISEASE; SUICIDE; TETRABENAZINE; U.S. FOOD AND DRUG ADMINISTRATION;

ADRENERGIC UPTAKE INHIBITORS; ADULT; DEPRESSION; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; SUICIDAL IDEATION; TETRABENAZINE;

EID: 84906923097     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-130071     Document Type: Article

References (18)

1. Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: An open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurol. 2009;9:62.
2. Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011;11:1509-23.
3. NDA 21-894 Xenazine® (tetrabenazine) Risk Evaluation and Mitigation Strategy. Food and Drug Administration.20. http://www.fda.gov/downloads/Drugs/DrugSafety/Postmarke tDrugSafetyInformationforPatientsandProviders/ucm129514. pdf
4. US Food and Drug Administration. NDA 21-894 Xenazine® (tetrabenazine): Risk Evaluation and Mitigation Strategy. 2012. http://www.fda.gov/downloads/Drugs/DrugSafety /PostmarketDrugSafetyInformationforPatientsandProviders/ ucm129514.pdf
5. Hayden MR, Leavitt BR, Yasothan U, Kirkpatrick P. Tetrabenazine. Nat Rev Drug Discov. 2009;8:17-8.
6. Guay DR. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother. 2010;8:331-73.
7. Huntington Study G. Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. Neurology. 2006;66:366-72.
8. Paulsen JS, Nehl C, Hoth KF, Kanz JE, Benjamin M, Conybeare R, McDowell B, Turner B. Depression and stages of Huntington’s disease. J Neuropsychiatry Clin Neurosci. 2005;17:496-502.
9. Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, DuffK, Kayson E, Biglan K, Shoulson I, Oakes D, Hayden M. Detection of Huntington’s disease decades before diagnosis: The Predict-HD study. J Neurol Neurosurg Psychiatry. 2008;79:874-80.
10. Schoenfeld M, Myers RH, Cupples LA, Berkman B, Sax DS, Clark E. Increased rate of suicide among patients with Huntington’s disease. J Neurol Neurosurg Psychiatry. 1984;47:1283-7.
11. Farrer LA. Suicide and attempted suicide in Huntington disease: Implications for preclinical testing of persons at risk. Am J Med Genet. 1986;24:305-11.
12. Sorensen SA, Fenger K. Causes of death in patients with Huntington’s disease and in unaffected first degree relatives. JMed Genet. 1992;29:911-4.
13. Paulsen JS, Hoth KF, Nehl C, Stierman L. Critical periods of suicide risk in Huntington’s disease. Am J Psychiatry. 2005;162:725-31.
14. Di Maio L, Squitieri F, Napolitano G, Campanella G, Trofatter JA, Conneally PM. Suicide risk in Huntington’s disease. J Med Genet. 1993;30:293-5.
15. The Huntington Study Group COHORT Investigators. Characterization of a large group of individuals with huntington disease and their relatives enrolled in the COHORT study. PLoS One. 2012;7:e29522.
16. Unified Huntington’s Disease Rating Scale: Reliability consistency. Huntington Study Group. Mov Disord. 1996;11:136-42.
17. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-98.
18. Hubers AA, van Duijn E, Roos RA, Craufurd D, Rickards H, Bernhard Landwehrmeyer G, van der Mast RC, Giltay EJ. Suicidal ideation in a European Huntington’s disease population. J Affect Disord. 2013.